Compass Therapeutics, Inc. Common Stock (CMPX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Compass Therapeutics, Inc. Common Stock (CMPX) is listed on Nasdaq, where it has traded since November 13, 2020.
- Listed On
- Nasdaq
- Listed Since
- November 13, 2020
- Employees
- 39
- Market Cap
- $137M
About Compass Therapeutics, Inc. Common Stock
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 210 institutions reported holding CMPX, with 165.7 million shares worth $363.4 million in aggregate. The largest reported holder was Tang Capital Management, with 18.0 million shares worth $39.4 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Tang Capital Management | 17,990,782 | $39M | Added 7.15% |
| Orbimed Advisors | 15,219,994 | $33M | Unchanged |
| Suvretta Capital Management | 14,101,159 | $31M | Reduced 1.44% |
| BlackRock | 11,281,781 | $25M | Added 18.68% |
| Vanguard | 11,060,021 | $24M | Added 32.92% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CMPX?
Compass Therapeutics, Inc. Common Stock (CMPX) is listed on Nasdaq, where it has traded since November 13, 2020.
Who are the largest institutional holders of CMPX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CMPX were Tang Capital Management, Orbimed Advisors and Suvretta Capital Management.
How many institutions own CMPX?
210 institutions reported a position in CMPX for the quarter ended June 30, 2026, worth $363.4 million in total.
Did institutions buy or sell CMPX last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for CMPX.
Every reported institutional holder, plus insider and congressional trades in CMPX, on SentiSense.